Global Custom Market Research Reports Provider Company

phone

Novelion Therapeutics Inc (NVLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 12 Oct 2018
  • Number of Pages: 79
  • Category: Company Profile
  • Country: Canada
Summary

Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company has two marketed products - Lomitapide, a small molecule microsomal triglyceride transfer protein inhibitor under the brand name JUXTAPID, and Metreleptin, a recombinant analog of human leptin under the brand name MYALEPT. Its other product candidate, zuretinol acetate, is an oral synthetic retenoid that can be used in the treatment of inherited retinal diseases. The company operates along with its subsidiaries across North America, South America, Europe and Asia. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc (NVLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novelion Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 13
Licensing Agreements 14
Aegerion Pharma Expands Licensing Agreement with Amryt Pharma 14
Equity Offering 15
QLT to Raise USD22 Million in Private Placement of Shares 15
Aralez Pharma Raises USD45 Million in Private Placement of Shares 17
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 19
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 20
Debt Offering 22
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 22
Asset Transactions 23
Mati Therapeutics Completes Acquisition Of Punctal Plug Delivery System From QLT For Up To US$21 Million 23
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 24
Acquisition 25
QLT Acquires Aegerion Pharma 25
Novelion Therapeutics Inc - Key Competitors 27
Novelion Therapeutics Inc - Key Employees 28
Novelion Therapeutics Inc - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Aug 07, 2018: Novelion Therapeutics Reports Second Quarter 2018 Financial Results 31
May 10, 2018: Novelion Therapeutics Reports First Quarter 2018Financial Results 34
Mar 15, 2018: Novelion Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 35
Nov 09, 2017: Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change 37
Aug 08, 2017: Novelion Therapeutics Reports Second Quarter 2017 Financial Results 39
May 09, 2017: Novelion Therapeutics Reports First Quarter 2017 Financial Results 42
Mar 15, 2017: Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results 44
Jan 09, 2017: Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook 47
Corporate Communications 48
Jul 03, 2018: Novelion Therapeutics Names Mark Corrigan As Executive Chair Of The Board Of Directors 48
Dec 04, 2017: Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer 49
Oct 31, 2017: Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer 50
Sep 11, 2017: Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors 51
Aug 02, 2017: Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors 52
Jun 01, 2017: Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D 53
Apr 19, 2017: Novelion Therapeutics Request to Voluntarily Delist from the Toronto Stock Exchange Granted 54
Mar 31, 2017: Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors 55
Legal and Regulatory 56
Jan 30, 2018: Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals 56
Jun 26, 2017: Novelion Therapeutics added to the Russell 3000 & Russell Microcap Indexes 57
Product News 58
09/22/2017: Criminal and civil actions filed against Aegerion Pharmaceuticals 58
09/15/2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology 59
08/23/2018: Novelion Therapeutics announces next phase of operational improvements 60
07/31/2018: Novelion Therapeutics Announces Marketing Authorization for MYALEPTA (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy 61
07/25/2017: Newly Published Long-term Study Shows Highly Positive Results for Lojuxta 62
06/25/2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions 63
06/12/2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association 64
06/01/2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy 65
05/05/2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology 66
04/04/2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society 67
03/30/2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society 69
03/06/2018: Amryt Pharma: Senior Management Appointment 71
01/23/2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency 72
Clinical Trials 73
Apr 27, 2017: Study Results of Real-World Experience of Lojuxta (lomitapide) Shows Improved Efficacy Over Clinical Trials of the Drug 73
Other Significant Developments 75
Aug 23, 2018: Novelion Therapeutics announces next phase of operational improvements 75
Feb 28, 2018: Novelion Therapeutics Observes Rare Disease Day 76
Jan 24, 2018: Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review 77
Nov 21, 2017: Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List Of Tables


Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novelion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Novelion Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aegerion Pharma Acquires Rights to Myalept from Amylin Pharma 13
Aegerion Pharma Expands Licensing Agreement with Amryt Pharma 14
QLT to Raise USD22 Million in Private Placement of Shares 15
Aralez Pharma Raises USD45 Million in Private Placement of Shares 17
Aegerion Pharma Completes Public Offering Of Common Stock For US$83 Million 19
Aegerion Pharma Completes Public Offering Of Common Stock For US$56 Million 20
Aegerion Pharma Raises USD325 Million in Private Placement of Notes Due 2019 22
Mati Therapeutics Completes Acquisition Of Punctal Plug Delivery System From QLT For Up To US$21 Million 23
Valeant Pharma Acquires Visudyne Business From QLT For Up To USD132.5 Million 24
QLT Acquires Aegerion Pharma 25
Novelion Therapeutics Inc, Key Competitors 27
Novelion Therapeutics Inc, Key Employees 28
Novelion Therapeutics Inc, Other Locations 29
Novelion Therapeutics Inc, Subsidiaries 29

List Of Figures


Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novelion Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution;

View Report

UDG Healthcare plc (UDG) formerly, United Drug plc is a provider of outsourced commercial solutions to healthcare companies. It offers supply chain, packaging, sales and marketing, medical and regulatory services

View Report

Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports